贝利尤单抗治疗系统性红斑狼疮的效果分析  

Effect analysis of belimumab in treatment of systemic lupus erythematosus

作　　者：徐男男 付文轶[1] 张宁(指导)[1] XU Nannan;FU Wenyi;ZHANG Ning(Shengjing Hospital of China Medical University,Shenyang 110004,China)

机构地区：[1]中国医科大学附属盛京医院,沈阳110004

出　　处：《中国免疫学杂志》2022年第18期2264-2268,共5页Chinese Journal of Immunology

基　　金：辽宁省自然科学基金项目(20180550987)资助。

摘　　要：目的:探讨贝利尤单抗治疗系统性红斑狼疮(SLE)的效果。方法:回顾性分析2020年12月9日至2021年11月16日在中国医科大学附属盛京医院经贝利尤单抗治疗的患者,统计患者的临床资料。采用配对t检验和配对Wilcoxon秩和符号检验,比较分析患者治疗前后各项指标差异。结果:回顾性纳入20例患者,贝利尤单抗中位治疗时间86 d,累计用药次数(5±3)次,贝利尤单抗应用前后,激素用量、SLE病情活动度2000(SLEDAI-2K)评分、抗双链DNA抗体(抗dsDNA抗体)、血清补体、免疫球蛋白、血沉、血红蛋白、24 h尿蛋白定量、血清白蛋白及D二聚体等指标差异均有统计学意义。结论:贝利尤单抗可以协助激素减量,同时对改善贫血、减轻蛋白尿、缓解低蛋白血症及体内高凝状态等具有一定效果。Objective:To investigate the effect of belimumab on systemic lupus erythematosus(SLE).Methods:Retrospective analysis was performed on patients treated with belimumab from December 9,2020,to November 16,2021,in Shengjing Hospital of China Medical University,and the clinical data of the patients were collected. Paired t-test and Wilcoxon signed-rank test were used to compare and analyze the differences of indicators before and after treatment.Results:Twenty patients were retrospectively enrolled. The median treatment time of belimumab was 86 days,and the cumulative number of treatments was(5±3)times. There were statistical differences in dosage of hormone,systemic lupus erythematosus disease activity index 2000(SLEDAI-2K)score,anti-dsDNA antibody,serum complement,immunoglobulin,erythrocyte sedimentation rate(ESR),hemoglobin,24-hour urine protein quantification,serum albumin,and D dimer before and after treating with belimumab.Conclusion:Belimumab can help reduce dosage of hormone,improve anemia,reduce proteinuria,relieve hypoproteinemia,and hypercoagulability in vivo.

关 键 词：系统性红斑狼疮 贝利尤单抗 SLEDAI-2K评分 治疗效果分析 

分 类 号：R593.241[医药卫生—内科学]